Eculizumab in Primary MPGN (EAGLE)
EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA
Sponsor: Alexion Pharma Italy s.r.l.
A PHASE2 clinical study on Membranoproliferative Glomerulonephritis, this trial is completed. The trial is conducted by Alexion Pharma Italy s.r.l. and has accumulated 8 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Mar 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alexion Pharma Italy s.r.l.
- Mario Negri Institute for Pharmacological Research
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bari, Italy , Bergamo, Italy , Bologna, Italy , Bolzano, Italy , Messina, Italy , Napoli, Italy , Padua, Italy , Rimini, Italy , Roma, Italy , Torino, Italy and 2 more locations